Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-12-22 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
TLX101 Glioblastoma Therapy - Clinical Update 2 pages 212.5KB
Regulatory Filings Classification · 95% confidence The document is a clinical progress update from Telix Pharmaceuticals Limited regarding the TLX101 therapy for glioblastoma. It provides detailed clinical trial data, patient outcomes, and future development plans. The content focuses on clinical and therapeutic progress rather than financial results, regulatory filings, or shareholder information. It is not an earnings release, annual report, or regulatory filing. The document is an update on clinical development, which is typically categorized under Regulatory Filings (RNS) as it does not fit into other specific financial or corporate filing categories. The length is under 5,000 characters and it is a standalone announcement rather than a full report or presentation.
2020-12-22 English
Change in substantial holding 4 pages 699.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001 Section 671B, titled 'Notice of Change of Interests of Substantial Holder.' It details changes in voting power and relevant interests of a substantial shareholder (FIL Limited) in Telix Pharmaceuticals Limited. The content includes dates, share transactions (buys and sells), voting power percentages, and associated entities. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes. The length and detail confirm it is the actual notification, not just an announcement or certification.
2020-12-16 English
Appendix 2A - issue of shares from exercise of options 15 pages 220.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A Application for quotation of securities' and is structured as a form for applying for the quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, dates, and specifics about options exercised and securities issued. This is a regulatory announcement related to the issuance and quotation of securities rather than a financial report or earnings release. It is not an annual report, audit report, earnings release, or management report. It is also not a proxy statement, dividend notice, or merger announcement. The document is a formal regulatory filing notifying the market and the exchange about new securities being quoted, consistent with the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed information rather than just a brief announcement or a certification, so it is not a Report Publication Announcement (RPA) or a certification filing. Therefore, the best classification is Regulatory Filings (RNS).
2020-12-16 English
Cleansing Notice under section 708A Corporations Act 1
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A of the Corporations Act related to the issuance of shares following the exercise of options. It references an Appendix 2A and confirms compliance with disclosure requirements. The content is about a capital issuance event and legal compliance notice rather than a full financial report or earnings release. The document length is short (1326 characters), and it is a formal announcement of share issuance without detailed financial data. Therefore, it fits best under Capital/Financing Update (CAP).
2020-12-16 English
Urologic Oncology Alliance with Mauna Kea Technologies 2 pages 202.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new scientific and clinical research collaboration between Telix Pharmaceuticals Limited and Mauna Kea Technologies. It describes the nature of the collaboration, the companies involved, and their respective technologies. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings information, and no detailed financial or operational report content. The document is an announcement of a partnership and research alliance, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. It is not a report, transcript, or financial statement. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is over 5,000 characters, so it is not a mere report publication announcement. Confidence is high given the clear nature of the content.
2020-12-15 English
New Drug Submission filed with Health Canada for TLX591-CDx 2 pages 217.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a New Drug Submission (NDS) with Health Canada for a prostate cancer imaging product by Telix Pharmaceuticals. It discusses regulatory submissions and approvals but does not contain financial data, earnings, management discussion, or detailed financial reports. It is not an annual or interim report, nor a call transcript or governance document. The content is primarily an update on regulatory and product development progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories.
2020-12-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.